Alvotech (ALVO)
5.51
-0.27
(-4.67%)
USD |
NASDAQ |
Oct 12, 15:13
Alvotech Net Income (Quarterly) : -66.82M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -66.82M |
| March 31, 2026 | 1.03M |
| December 31, 2025 | -108.55M |
| September 30, 2025 | -5.252M |
| June 30, 2025 | 32.04M |
| March 31, 2025 | 109.68M |
| December 31, 2024 | -66.97M |
| September 30, 2024 | -11.39M |
| June 30, 2024 | 65.22M |
| March 31, 2024 | -218.73M |
| December 31, 2023 | -276.56M |
| September 30, 2023 | -188.32M |
| Date | Value |
|---|---|
| June 30, 2023 | 189.33M |
| March 31, 2023 | -276.18M |
| December 31, 2022 | -320.51M |
| September 30, 2022 | -8.602M |
| March 31, 2022 | -76.98M |
| December 31, 2021 | -3.949M |
| September 30, 2021 | -81.32M |
| June 30, 2021 | -0.2257M |
| March 31, 2021 | 7.069M |
| December 31, 2020 | -9.236M |
| September 30, 2020 | -1.636M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Regeneron Pharmaceuticals, Inc. | 1.297B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 105.77M |
| Total Expenses (Quarterly) | 172.59M |
| EPS Diluted (Quarterly) | -0.1873 |
| Enterprise Value | 3.371B |
| Gross Profit Margin (Quarterly) | 50.65% |
| Profit Margin (Quarterly) | -63.17% |
| Earnings Yield | -10.12% |
| Operating Earnings Yield | 2.52% |
| Normalized Earnings Yield | -10.12 |